AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05433129 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Transient hyperemic response
Description: The transient hyperemic response will be tested via carotid compression method. This test will consist of 5 carotid compressions lasting 5 seconds each with a 60 seconds interval between each compression to allow normalization of the CBF to precompression levels, and the total time for this block would be 6 minutes. The ipsilateral common carotid artery will be compressed for this method, and the response of the middle cerebral artery (MCA) blood flow velocity will be assessed using transcranial doppler (TCD) probe (EMS-9D, Delica). The carotid compressions will only be accepted when there is no further decrease in blood flow velocity can be achieved and stable conditions remained during the whole period of the compression. Otherwise, the compression will be terminated and repeated again after 60 seconds. Satisfactory compression is typically considered to result in a reduction in MCA velocity of 50%, at a minimum.
Study NCT05433129 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Orthostatic challenge
Description: The orthostatic challenge response will be evaluated by lying-to-sit and sit-to-stand methods 5 times where sitting and standing positions will be held for 3 minutes each for a total block time of 35 minutes. A baseline in lying position will be collected at the start of the block, then the position will be changed from lying to sit for 3 minutes and then position will be changed to standing for another 3 minutes.
Study NCT05433129 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Vascular chemo-reactivity
Description: vascular chemo-reactivity will be assessed by varying CO2 concentrations through slow and fast breathing exercises with Capnostream 35 Portable Respiratory Monitor (Medtronic Canada) to monitor EtCO2 through nose clip. The breathing trials will occur two times and each of them will have fast and slow trials along with an interval of normal breathing. First time, the normal, fast and slow breathing trials will be 2.5 minutes long while the second time, these breathing trials will be 1.5 minutes long. The normal respiratory rate for adults is 12 breaths/minute, the target slow respiratory rate will be 5 breaths/minute and fast respiratory rate will be 25 breaths/minute as set by metronome. It has been shown that the EtCO2 has a 10% increase during hypoventilation and almost 50% decrease during hyperventilation compared to normal breathing.
Study NCT05433129 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Neurovascular coupling
Description: The fourth block will evaluate the neurovascular coupling using Automated Neuropsychological Assessment Metrics (ANAM) General Neuropsychological Screening (GNS) Clinical Toolkit which contains 5 tests explained as follows 1) Standard Continuous Performance test will assess sustained attention, concentration and working memory. 2) Manikin test will assess 3D spatial rotation ability, left-right orientation, problem solving and attention. 3) Pursuit Tracking test will measure the visuo-motor control. 4) Switching test will assess divided attention, mental flexibility, and executive function. 5) Stroop test will assess the processing speed, selective attention, interference, and executive functioning with three trial blocks.
Study NCT06393712 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered intrathecally
Study NCT06393712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-APP
Description: ALN-APP will be administered intrathecally
Study NCT06393712 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ALN-APP
Description: ALN-APP will be administered intrathecally
Study NCT05878522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sisunatovir
Description: 6 capsules administered Q12 hours for 5 doses
Study NCT05878522 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 6 capsules administered Q12 hours for 5 doses
Study NCT05759169 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foot Bath Tub
Description: A foot bath is generally a form of rest and care where feet are put in water. Feet are body areas where fatigue is most felt as organs that carry the body's total weight. This study uses a specially designed foot bath bath bath bath to give the patients in the experimental group foot bath. The cuvette has four-stage water heating (35-45°C). It has a magnetic field and operates at 390 Watts. It has a splash guard. The sole features non-slip rubber feet. It has a heat shield feature because it has a double wall construction for heat isolation.
Study NCT05294770 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optisource® Plus: Very Low Calorie Diet treatment
Description: Patients randomized to this group will receive a VLCD, which consists of a replacement diet based on a liquid enteral formula (46% carbohydrates, 19% fat and 32% protein; 654 Kcal/day): OPTISOURCE® PLUS, taken as 3 shakes a day. In addition, participants may consume 2 pieces of fruit/day (about 250 g/day) and up to 300 g/day of non-starchy vegetables according to the list of foods that will be provided to patients; this will constitute a total daily energy intake of about 800 Kcal. In addition, protein intake (0.8 to 1.3 g/kg/day of adjusted weight) will be adjusted by adding Resource® Instant Protein individually, depending on the anthropometry and the renal function of the patients (to preserve fat free mass, whose loss has been correlated with subsequent weight recovery)
Study NCT05294770 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hypocaloric Mediterranean Diet
Description: Randomized participants in this group will be recommended to follow a Mediterranean Diet, based on the use of olive oil as the main source of visible fat and regular consumption of vegetables (≥2 servings/day), fruits (≥3 servings/day), legumes (≥3 servings/week) and fish (≥3 times a week), reducing the consumption of red meat or sausages (\<2 times a week) and eliminating the consumption of sugary drinks, pastries or industrial pastries. In this Mediterranean Diet, an energy restriction of 30% of the estimated energy needs (Harris-Benedict equation) will be established.
Study NCT04716400 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stop sexual harassment
Description: Teachers will be introduced to a digital course on the prevention of sexual- and gendered harassment. In the course they will provided with a manual containing eight lessons to be held for the pupils. Each lesson will last 45 minutes and consist of a short lecture and practical activities for the pupils.
Study NCT06424925 — intervention group
Intervention type: OTHER
Intervention: Artificial intelligence for the prediction of clinical outcomes
Description: Use of artificial intelligence (AI) for the prediction of clinical outcomes such as death and complications in patients hospitalized for COVID pneumonia during the 4 pandemic waves
Study NCT05164848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JMT101
Description: JMT101 will be administered intravenously at 6 mg/kg every 2 weeks (q2w) in each 28-week cycle.
Study NCT05164848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: Afatinib will be administered orally at 30 mg or 40 mg per day (qd) in each 28-week cycle.
Study NCT05878522 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: moxifloxacin
Description: 6 capsules of placebo administered Q12 hours for 4 doses, followed by a single tablet of moxifloxacin
Study NCT05878522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sisunatovir
Description: 7 capsules administered Q12 hours for 5 doses
Study NCT06394193 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community-based participatory research intervention
Description: Two training sessions (roughly two hours each) to train them in the intervention structure and curriculum
Study NCT05660265 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered.
Study NCT05699434 — intervention group
Intervention type: BEHAVIORAL
Intervention: Obstetrics and Gynecology residents and experts'
Description: Obstetrics and Gynecology residents and experts' knowledge of, attitudes toward, practice behaviors, and self-confidence levels of caring for lesbian, bisexual, and transgender (LBT+) patients in Turkey (Istanbul)
Study NCT04846608 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: Observation
Study NCT05897762 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Tele rehabilitation Group
Description: It has been determined that the telerehabilitation method applied in chronic hemiplegic patients increases daily living activities, upper extremity functionality, and spasticity levels decrease.
Study NCT06157333 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The Magstim Rapid2 Plus Magnetic Stimulator (Magstim, Whitland, Dyfed, UK)
Description: The Magstim Rapid2 Plus Magnetic Stimulator (Magstim, Whitland, Dyfed, UK) device available in our center was used.
Study NCT06157333 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: The Magstim Rapid2 Plus Magnetic Stimulator (Magstim, Whitland, Dyfed, UK)
Description: The Magstim Rapid2 Plus Magnetic Stimulator (Magstim, Whitland, Dyfed, UK) device available in our center was used.
Study NCT06545526 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: celecoxib monotherapy
Description: Patients will be randomly assigned in a 1:1 ratio to receive celecoxib monotherapy or combination of celecoxib and metformin orally for 6 months: celecoxib \[400mg, twice a day\] in arm 1, celecoxib \[400mg, twice a day\] and metformin \[1g, twice a day\] in arm 2.
Study NCT06545526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib and metformin combination
Description: Patients will be randomly assigned in a 1:1 ratio to receive celecoxib monotherapy or combination of celecoxib and metformin orally for 6 months: celecoxib \[400mg, twice a day\] in arm 1, celecoxib \[400mg, twice a day\] and metformin \[1g, twice a day\] in arm 2.
Study NCT04643782 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ANNE Sleep
Description: ANNE sleep system
Study NCT04831125 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: Data collection on the use of pacemaker, implantable cardioverter-defibrillator (ICD), and cardiac resynchronization therapy (CRT) devices and leads that are approved for clinical use.
Study NCT06428006 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for insomnia
Description: The general sessions outlines are as follows with each session:~Session 1: determine treatment plan, set up sleep schedule and stimulus control, discuss strategies for how to stay awake to prescribed hour and what to do if wake up in middle of night, sleep hygiene education Session 2: continue upward titration of total sleep time, review sleep hygiene; introduce diaphragmatic breathing Session 3: continue upward titration of total sleep time, introduce mindfulness Session 4: continue upward titration of total sleep time, introduce progressive muscle relaxation Session 5: continue upward titration of total sleep time, discuss negative sleep beliefs Session 6: assess global treatment gains, discuss relapse prevention
Study NCT06428006 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep and lifestyle education
Description: The general sessions outlines are as follows with each session:~Session 1: Basic sleep education, stretching exercises Session 2: Sleep hygiene education (environmental factors \& sleep positions), stretching exercises Session 3: Sleep hygiene education (lifestyle factors), stretching exercises Session 4: Diet recommendations, stretching exercises Session 5: Exercises recommendations, stretching exercises Session 6: Discus maintaining achievements \& preventing relapses, stretching exercises
Study NCT06083051 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 6Fr Percuflex ureteral stents
Description: The Percuflex stent is a 6Fr polymeric, hydrophilic coated stent that is routinely used post ureteroscopy with laser lithotripsy.
Study NCT06083051 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 6Fr Tria ureteral stents
Description: The Tria stent is a new stent that is designed to soften at body temperature after placement, with an additional coating that prevents calcium and magnesium build up. This is intended to increase patient tolerability of the stent. 6 Fr is the diameter.
Study NCT06083051 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 4.8Fr Tria ureteral stents
Description: The Tria stent is a new stent that is designed to soften at body temperature after placement, with an additional coating that prevents calcium and magnesium build up. This is intended to increase patient tolerability of the stent. 4.8 Fr is the diameter.
Study NCT06083051 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 4.8Fr Percuflex ureteral stents
Description: The Percuflex stent is a 4.8Fr polymeric, hydrophilic coated stent that is routinely used post ureteroscopy with laser lithotripsy.
Study NCT06552377 — intervention group
Intervention type: DEVICE
Intervention: Ultrasound Attenuation imaging measurement
Description: Participant to undergo conventional ultrasound scanning with attenuation measurement as well.
Study NCT06669858 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: manual therapy
Description: In first session 6 techniques were applied to favorise fluids circulation, respiratory mecanism end equilibration of pressions (all were external soft tissue techniques, without manipulation): on cervico dorsal hinge, on cranial diaphragm, on thoracic diaphragm, on pelvic diaphram, on liver and spleen organ, on lumbar fasciae.~In second session 6 techniques were applied in order to improve quality and quantity of legs and pelvis mobility (all were external sof tissue techniques, without manipulation) : on cervico dorsal hinge, on cranial diaphragm, on thoracic diaphragm, on pelvic diaphram, on pubic symphysis, on legs and pelvis and on lumbar fasciae
Study NCT06669858 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Wide ligth touch pressure applied with the 2 hand at day 2-4 and day 90
Study NCT05097378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib + Binimetinib
Description: Encorafenib is a potent and highly selective ATP-competitive small molecule RAF kinase inhibitor, which suppresses the RAF/MEK/ERK pathway in tumour cells expressing several mutated forms of BRAF kinase (V600E, D and K).~Binimetinib is an ATP-uncompetitive, reversible inhibitor of the kinase activity of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2. Binimetinib inhibits activation of MEK by BRAF and inhibits MEK kinase activity
Study NCT05097378 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Adjuvant Treatment
Description: Standard Adjuvant Treatment
Study NCT04924114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-6194
Description: Subcutaneous injection
Study NCT04924114 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MK-6194-matching placebo
Description: Subcutaneous injection
Study NCT06312774 — intervention group
Intervention type: OTHER
Intervention: This is observational study
Description: This is observational study
Study NCT06218888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab 200mg，D1, Q3W
Study NCT06218888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Description: Fruquintinib 3mg ,D1-D14, Q3W
Study NCT06218888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: Chidamide 30mg
Study NCT05245617 — intervention group
Intervention type: DEVICE
Intervention: JuniOrtho™ Plating System™
Description: The patient underwent surgery for the application of JPS for treatment of deformity or traumatic fracture.
Study NCT05448768 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TBS for Amyloid-positive MCI
Description: The investigators will perform standard intermittent TBS (iTBS) parameters to left DLPFC of every patient in the study. The frequency parameters of TBS are 3-pulse 50-Hz bursts, every 200 ms at 5 Hz, and the intensity is 90% of active motor threshold. A single session of iTBS contains 2 s of TBS repeated every 10 s for 20 times. In this study, The investigators will give two sessions of iTBS separated by 15 min.
Study NCT05448768 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TBS for Amyloid-negative MCI
Description: The investigators will perform standard intermittent TBS (iTBS) parameters to left DLPFC of every patient in the study. The frequency parameters of TBS are 3-pulse 50-Hz bursts, every 200 ms at 5 Hz, and the intensity is 90% of active motor threshold. A single session of iTBS contains 2 s of TBS repeated every 10 s for 20 times. In this study, The investigators will give two sessions of iTBS separated by 15 min.
Study NCT06500299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDM1002 100 mg QD
Description: HDM1002 tablets 100mg daily, 12weeks
Study NCT06500299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDM1002 200 mg QD 12weeks
Description: HDM1002 tablets 200mg daily, 12weeks
Study NCT06500299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDM1002 400 mg QD 12weeks
Description: HDM1002 tablets 400mg daily, 12weeks
Study NCT06500299 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be provided
Study NCT04613414 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Management
Description: Scheduled for sleep physician appointment within 1 month of home sleep apnea test/triage
Study NCT05035901 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: visual-perception motor-coordination integration program
Description: Visual-perception motor-coordination integration program (CCVPMCI) is a Chinese characteristic-based VMI-focused program involving the most Chinese-handwriting-related skills training. CCVPMCI mainly emphasizes the training role of visual-motor integration. The idea of CCVPMCI program will involve (1) visual motor integration training affiliated with visual perception and motor coordination as warm-up exercise, (2) more focus on visual spatial perception in connect with unique visual structure of Chinese characters, (3) the trace or component elements of Chinese characters as the interesting practice material and (4) appropriate challenge for learning.
Study NCT06669052 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: 30 mg liposomal iron, capsules
Description: a dietary supplement capsule, of mainly 30 mg liposomal iron, and Vitamin C 70mg, vitamin D3 400IU, vitamin B6 1.75 mcg, Folate 1000 mcg, b=vitamin B12 10 mcg. all in capsulated in 1 Hard gelatin capsule
Study NCT05382416 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SHARE! Peer Toolkit Training
Description: The SHARE! Peer Toolkit training is designed to improve the performance of peer workers in their provision of peer support. The training covers each of the 12 tools in the Peer Toolkit, which are taught through brief presentations followed by group discussions and interactive exercises to help people competently use each of the tools. Training sessions are typically two hours each, three times per week for 10 weeks.
Study NCT06161909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sintilimab
Description: 200mg fixed dose Q3W,1 year
Study NCT05459844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutetium[177Lu] Oxodotreotide Injection
Description: Four administrations of 7.4 GBq (200 mCi) Lutetium\[177Lu\] Oxodotreotide Injection administered at 8 +/- 1-week intervals, which could be extended up to 16 weeks to accommodate resolving acute toxicity.
Study NCT05459844 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octreotide LAR
Description: 60 mg Octreotide LAR treatment was given to the participants every 4 weeks (i.m. injections) until the end of the study, unless the participant progressed or died.
Study NCT06398353 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Real acupuncture
Description: Real acupuncture twice a week for two weeks
Study NCT06398353 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Real acupuncture
Description: Real acupuncture twice a week for two weeks
Study NCT06398353 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham acupuncture
Description: Sham acupuncture twice a week for two weeks
Study NCT06398353 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture
Description: Sham acupuncture twice a week for two weeks
Study NCT06537986 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurocognitive and psychosocial intervention module
Description: The module comprised of various intervention methods that include- I. Cognitive Retraining: Pen-and-paper-based cognitive rehabilitation program that is divided into five hierarchically graded modules: Attention, Visual Processing, Memory, Information Processing, and Executive Functions.~2.Cognitive-behavioral interventions. Cognitive-behavioral interventions would be carried out for activities scheduling, problem-solving teachings, anger management techniques, modifications of negative cognitions, stigma address measures, and irrational beliefs about epilepsy, etc.~3. Marital/Family counseling: Marital/family counseling would be done to ensure family understanding of the patient's illness, his/her treatment, prognosis, and outcome. Family complications arising due to illness would also be discussed. Individual and personal needs of the husband, a wife will also be discussed.